128 related articles for article (PubMed ID: 33404002)
21. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
22. PIN-like (Ductal) Adenocarcinoma of the Prostate.
Paulk A; Giannico G; Epstein JI
Am J Surg Pathol; 2018 Dec; 42(12):1693-1700. PubMed ID: 30138215
[TBL] [Abstract][Full Text] [Related]
23. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
24. Assessment of prostate cancer prognostic Gleason grade group using zonal-specific features extracted from biparametric MRI using a KNN classifier.
Jensen C; Carl J; Boesen L; Langkilde NC; Østergaard LR
J Appl Clin Med Phys; 2019 Feb; 20(2):146-153. PubMed ID: 30712281
[TBL] [Abstract][Full Text] [Related]
25. The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.
Helpap B; Ringli D; Tonhauser J; Poser I; Breul J; Gevensleben H; Seifert HH
Pathol Oncol Res; 2016 Apr; 22(2):349-56. PubMed ID: 26563277
[TBL] [Abstract][Full Text] [Related]
26. Interobserver reproducibility of percent Gleason grade 4/5 in prostate biopsies.
Glaessgen A; Hamberg H; Pihl CG; Sundelin B; Nilsson B; Egevad L
J Urol; 2004 Feb; 171(2 Pt 1):664-7. PubMed ID: 14713782
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.
Fanning DM; Kay E; Fan Y; Fitzpatrick JM; Watson RW
BJU Int; 2010 Mar; 105(5):631-5. PubMed ID: 19732053
[TBL] [Abstract][Full Text] [Related]
28. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
Shah RB; Nguyen JK; Przybycin CG; Reynolds JP; Cox R; Myles J; Klein E; McKenney JK
Histopathology; 2019 Sep; 75(3):346-353. PubMed ID: 31012493
[TBL] [Abstract][Full Text] [Related]
29. Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population.
Rubio-Briones J; Borque-Fernando A; Esteban LM; Mascarós JM; Ramírez-Backhaus M; Casanova J; Collado A; Mir C; Gómez-Ferrer A; Wong A; Aragón F; Calatrava A; López-Guerrero JA; Groskopf J; Schalken J; Van Criekinge W; Domínguez-Escrig J
Prostate; 2020 May; 80(6):500-507. PubMed ID: 32077525
[TBL] [Abstract][Full Text] [Related]
30. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
[TBL] [Abstract][Full Text] [Related]
31. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
32. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
33. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
34. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.
Wang H; Gu L; Wu Y; Feng D; Duan J; Wang X; Huang Y; Wu S; Chen J; Luo G; Zhang X
BMC Cancer; 2017 Sep; 17(1):629. PubMed ID: 28874127
[TBL] [Abstract][Full Text] [Related]
35. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
Wissing M; Brimo F; Chevalier S; Scarlata E; McKercher G; O'Flaherty A; Aprikian S; Thibodeau V; Saad F; Carmel M; Lacombe L; Têtu B; Ekindi-Ndongo N; Latour M; Trudel D; Aprikian A
BJU Int; 2019 Apr; 123(4):624-631. PubMed ID: 30113732
[TBL] [Abstract][Full Text] [Related]
36. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.
Kim J; Davis JW; Klein EA; Magi-Galluzzi C; Lotan Y; Ward JF; Pisters LL; Basler JW; Pettaway CA; Stephenson A; Li Ning Tapia EM; Efstathiou E; Wang X; Do KA; Lee JJ; Gorlov IP; Vornik LA; Hoque AM; Prokhorova IN; Parnes HL; Lippman SM; Thompson IM; Brown PH; Logothetis CJ; Troncoso P
EBioMedicine; 2016 May; 7():85-93. PubMed ID: 27322462
[TBL] [Abstract][Full Text] [Related]
37. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
38. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
39. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
40. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
